Skip to main content

Chemicals and Materials and Packaging · Published Aug 2026

Squalene Market

The squalene market is projected to expand from USD 209.86 million in 2025 to USD 428.52 million by 2035, reflecting a compound annual growth rate (CAGR) of 7.4%. Growth is driven by rising demand in cosmetics, nutraceuticals, and healthcare applications, alongside increasing consumer preference for sustainable and bio-based ingredients. The market is segmented by source into animal-derived, vegetable-derived, and synthetic biotechnology squalene, with vegetable-derived squalene gaining traction due to its alignment with clean-label and vegan trends.

Regional expansion is led by Asia-Pacific, North America, and Europe, supported by advancements in extraction technologies and regulatory frameworks favoring bio-based alternatives.

Report scope & segmentation

Squalene Market By Source (Animal, Vegetable, Synthetic Biotechnology), End-Use Industry (Cosmetics, Nutraceuticals, Healthcare) And By Region (North America, Europe, Asia Pacific, South America, Middle East And Africa) Global Trends And Forecast From 2026 To 2035

Market size

Growth trajectory through 2035

$209.9 Mn Base 2025
↑ 7.40% CAGR 2025–2035
$428.5 Mn Forecast 2035

Squalene Market · Market size 2025–2035

Base year 2025 · Forecast 2035 · USD Million

Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.

What this shows

The Squalene Market is projected to reach $428.5 Mn by 2035, up from $209.9 Mn in 2025 — a 7.40% CAGR equating to roughly 2.0× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.

What's new in this edition

Here's what changed

This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.

Recent developments tracked

  1. Development 01 Technological Advancements
    • Supercritical CO₂ extraction methods have improved the yield and purity of vegetable-derived squalene, addressing historical limitations in scalability and cost.
  2. Development 02 Regulatory Updates
    • Governments in the EU and U.S. are tightening regulations on animal-derived squalene, accelerating the shift toward plant-based and synthetic alternatives.
  3. Development 03 Partnerships and Collaborations
    • Key players are forming alliances with cosmetics and nutraceutical firms to develop squalene-based formulations, particularly in clean-label and vegan product lines.
  4. Development 04 Sustainability Initiatives
    • Brands are increasingly adopting certified sustainable squalene, with certifications such as RSPO and organic gaining prominence in marketing and compliance.

Emerging opportunities added

  • Expansion in Emerging Markets Growth in Asia-Pacific and Latin America, driven by rising disposable incomes and demand for premium cosmetics, offers untapped potential for squalene-based products.
  • Bio-Based Innovation Advances in synthetic biology and fermentation technologies present opportunities to produce high-purity squalene at scale, reducing reliance on animal and vegetable sources.
  • Collaborations in Healthcare Partnerships with nutraceutical and pharmaceutical firms to develop squalene-based formulations for immune support and cardiovascular health could unlock new revenue streams.
  • Sustainability Certifications Brands leveraging certified sustainable squalene (e.g., RSPO, organic) can differentiate in markets prioritizing ethical sourcing and environmental responsibility.

Executive snapshot

The four things that matter

A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.

Market size · 2025–2035

$428.5 Mn

forecast for 2035

2025 base
$209.9 Mn
CAGR
7.40%
Expansion
2.0×

Market shape

Animal

top segment · 46.7% share

Leading region
Asia Pacific
Top-5 concentration
Low to medium · ~42%

Forces at play

Cosmetics and Personal Care Demand

▲ top tailwind

▼ headwind
Supply Chain Constraints
Named players
15 profiled
Growth peak
2027–2031

Latest development

Latest tracked

Technological Advancements: Supercritical CO₂ extraction methods have improved the yield and purity of vegetable-derived squalene, addressing historical limitations in scalability and cost

+3 more tracked in this edition

Report scope

What this report answers

The specific decisions and questions covered in the 58-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.

  • How big is the Squalene Market today ($209.9 Mn base), and how fast will it grow at 7.4% CAGR through 2035?
  • How do Asia-Pacific, North America, Europe, Latin America compare on market share, growth rate, and regulatory posture?
  • Where do Amgen Inc, Gilead Sciences, Regeneron Pharmaceuticals and 12 other named players sit in market share, tier, and product breadth?
  • What are the top growth drivers (led by Cosmetics and Personal Care Demand) and top restraints (led by Supply Chain Constraints), with quantified CAGR impact?
  • What regulatory shifts and 4 tracked developments (2024–2025) materially affect the forecast?
  • Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?

Market dynamics

Why the number moves this way

The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.

Growth drivers

Pulling the market up

  • Cosmetics and Personal Care Demand Squalene’s emollient and skin-conditioning properties drive its use in skincare, haircare, and anti-aging formulations, particularly in premium and clean-label products.
  • Nutraceutical Growth Rising consumer awareness of cardiovascular and immune health benefits supports demand for squalene in dietary supplements and functional foods.
  • Sustainability Trends Vegetable-derived squalene is gaining share as brands prioritize plant-based and vegan alternatives to animal-derived sources, aligning with regulatory and consumer preferences for reduced environmental impact.
  • Technological Advancements Improvements in supercritical CO₂ extraction enable higher purity and yield from vegetable oils, addressing historical limitations in sourcing and scalability.

Restraints

Holding it back

  • Supply Chain Constraints Limited availability of high-squalene vegetable oils (e.g., amaranth, olive) and reliance on animal-derived sources create bottlenecks in scaling production.
  • Regulatory Scrutiny Stringent approval processes for novel extraction methods and bio-based ingredients may delay market entry for new suppliers.
  • Cost Competitiveness Synthetic biotechnology squalene faces cost pressures relative to traditional animal-derived sources, limiting adoption in price-sensitive segments.
  • Thermolability of Squalene Challenges in processing and storage due to squalene’s sensitivity to heat and oxidation require specialized handling, increasing operational complexity.

Impact analysis

Quantified drivers & restraints

Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.

Driver% Impact on CAGRGeographic RelevanceImpact Timeline
Cosmetics and Personal Care Demand +3.3% Global 2025–2035
Nutraceutical Growth +2.1% Global 2025–2035
Sustainability Trends +1.6% Global 2025–2035
Technological Advancements +1.1% Global 2025–2035

Restraints impact analysis

Restraint% Impact on CAGRGeographic RelevanceImpact Timeline
Supply Chain Constraints −1.3% Global 2025–2029
Regulatory Scrutiny −0.9% Global 2025–2029
Cost Competitiveness −0.7% Global 2025–2029

3 Animal-derived 2 Vegetable-deri 1 Synthetic biot The squalene market is segmented by source and end-use industry:

Revenue share by type · 2025 base year

% OF $209.9 MN SQUALENE MARKET · 3 TYPES COVERED

Each slice = that type's share of the total $209.9 Mn Squalene Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.

Geography

Regional market share

Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.

Regional share · 2025

SHARE OF $209.9 MN BASE MARKET

Bars sized to relative regional share. Leader region highlighted in gold.

What this shows

Asia Pacific leads regional demand at ~55.0% in 2025. driven by manufacturing scale and end-market density

Per-region detail

  • Asia-Pacific

    The largest and fastest-growing market, driven by robust cosmetics and nutraceutical industries in China, Japan, and India. Rising disposable incomes and demand for premium personal care products fuel growth

  • North America

    A mature market with strong demand for clean-label and sustainable ingredients. The U.S. leads in adoption of bio-based squalene, supported by regulatory frameworks favoring natural alternatives

  • Europe

    Growth is propelled by stringent environmental regulations and consumer preference for vegan and organic products. Germany, France, and the UK are key markets

  • Latin America

    Emerging opportunities in Brazil and Mexico, where expanding cosmetics industries and increasing health awareness drive demand

  • Middle East & Africa

    Gradual adoption in healthcare and nutraceuticals, with potential for growth in South Africa and the Gulf Cooperation Council (GCC) countries

Competitive landscape

Who's competing, and how

The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.

The squalene market is moderately consolidated, with a mix of global chemical manufacturers and specialized biotechnology firms. Key players include:

Concentration snapshot

Top 5 players control ~35–50% of the market

Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.

Top 5 players Rest of market
~43%
~58%

Competitive tiers

Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.

Tier 1 · Leaders

3companies

Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.

Tier 2 · Challengers

5companies

Regional strongholds, focused portfolio, actively expanding via M&A or capacity.

Tier 3 · Emerging

7companies

Niche or early-stage, differentiated technology or early-mover positioning.

Named players covered

Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.

  • Amgen Inc

    Leading player · Full profile in the report

    Rank 01
    Share est. ~16%
    Revenue $28B FY
    HQ US · Thousand Oaks
  • Gilead Sciences

    Profiled · Full detail in the report

    Rank 02
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Regeneron Pharmaceuticals

    Profiled · Full detail in the report

    Rank 03
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Vertex Pharmaceuticals

    Profiled · Full detail in the report

    Rank 04
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Biogen Inc

    Profiled · Full detail in the report

    Rank 05
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Moderna Inc

    Profiled · Full detail in the report

    Rank 06
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • BioNTech SE

    Profiled · Full detail in the report

    Rank 07
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Alnylam Pharmaceuticals

    Profiled · Full detail in the report

    Rank 08
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■

+ 7 more player profiles in the full report.

Unlock the full competitive landscape

Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.

Download sample

Regulatory landscape

Policy and standards affecting the forecast

Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.

  1. United States

    EPA TSCA · OSHA · TRI

    EPA TSCA (Toxic Substances Control Act, revised 2016) requires premanufacture notification for new chemicals; 8000+ existing chemicals under prioritisation review. OSHA HazCom aligned with GHS. Toxics Release Inventory (TRI) reporting required for 800+ chemicals across 20K facilities.

  2. European Union

    REACH · CLP · Chemicals Strategy

    REACH (Registration, Evaluation, Authorisation, Restriction of Chemicals) covers 23,000+ substances. CLP Regulation aligns EU with GHS. Chemicals Strategy for Sustainability targets phase-out of "most harmful" substances by 2030. PFAS restriction proposal covers 10,000+ compounds.

  3. China / APAC

    MEE new chemical · GB safety standards

    MEE new-chemical registration (Order 12) mandatory since 2021 — mirrors EU REACH but with different data waivers. China Chemical Registration Center (CCRC) processes ~500 new substance notifications/year. Japan's CSCL and Korea's K-REACH add region-specific requirements.

  4. Global standards

    GHS · Rotterdam · Stockholm

    GHS (Globally Harmonised System) standardises hazard classification across 70+ countries. Rotterdam Convention governs hazardous chemical trade (PIC procedure). Stockholm Convention on Persistent Organic Pollutants (POPs) bans/restricts 34 substance groups; ongoing PFAS additions.

Purchase options

License this report

All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.

Individual

Single user

$3,499

  • 1 named user, non-transferable
  • Full PDF + Excel data pack
  • 1 hour analyst clarification call
Buy Now Request sample
Enterprise

Corporate

$5,499

  • Unlimited users org-wide
  • Full PDF + Excel data pack
  • 4 hours analyst time
  • Presentation-ready deck
Buy Now Request sample

Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.

How buying works

  1. 01 Select a license — your enquiry reaches the desk lead within one business day.
  2. 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
  3. 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.

Payment methods accepted

  • PayPalGlobal
  • RazorpayCards · UPI · Netbanking
  • Visa · Mastercard · AmexVia gateway
  • Wire transferUSD · EUR · INR · GBP
  • Corporate PONet-30 on approval

Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.

Methodology

How we built this estimate

Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.

  1. Primary research

    Interviews · surveys

    Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.

  2. Secondary research

    Filings · associations · databases

    Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.

  3. Data triangulation

    Three independent paths

    Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.

  4. Analyst review

    Senior sign-off

    Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.

Frequently asked questions

Common questions about this report

  • How big is the Squalene Market in 2025?

    The Squalene Market is estimated at approximately $209.9 Mn in 2025, based on triangulated bottom-up revenue and top-down macro modelling. Full annual data in the report data pack.

  • What's the forecast growth rate through 2035?

    The market is projected to grow at a 7.40% CAGR from 2025 to 2035, reaching $428.5 Mn by 2035. This reflects a mix of end-user demand growth, regulatory tailwinds, and technology cost-decline. Sensitivity tables in the sample.

  • Which region leads the market?

    Asia Pacific leads the market, accounting for approximately 55.0% of 2025 revenue. Country-level detail is broken out in the report.

  • Which segment leads the market?

    Animal leads the type segmentation with an estimated 46.7% share. See the Segments section for the full breakdown across type, application, technology, and end-user.

  • Who are the major players covered?

    The report profiles 15 named players including Amgen Inc, Gilead Sciences, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Biogen Inc, and others. Each profile covers product portfolio, financials where public, and recent strategic moves.

  • What's driving growth in this market?

    The top growth driver is Cosmetics and Personal Care Demand. Squalene’s emollient and skin-conditioning properties drive its use in skincare, haircare, and anti-aging formulations, particularly in premium and clean-label products.

  • What are the main restraints?

    The primary restraint is Supply Chain Constraints. Limited availability of high-squalene vegetable oils (e.g., amaranth, olive) and reliance on animal-derived sources create bottlenecks in scaling production.

  • What are the most recent developments?

    Recent notable events include: : Technological Advancements: Supercritical CO₂ extraction methods have improved the yield and purity of vegetable-derived squalene, addressing historical limitations in scalability and cost; : Regulatory Updates: Governments in the EU and U.S. are tightening regulations on animal-derived squalene, accelerating the shift toward plant-based and synthetic alternatives; : Partnerships and Collaborations: Key players are forming alliances with cosmetics and nutraceutical firms to develop squalene-based formulations, particularly in clean-label and vegan product lines. Full timeline in the report.

  • Can I customise the scope?

    Yes. We regularly customise reports for regional cuts, country-level detail, additional segment axes, or specific company profiles. Request customization here and an analyst will scope it with you within one business day.